Sherlock Biosciences have discovered a new thermostable Cas nuclease that enables real-time detection of RNA and or DNA targets, the company says in a press release. The new Cas nuclease will have broad implications for the SHERLOCK™ CRISPR-based method to detect and quantify specific genetic sequences that are already used for Covid-19 diagnosis.
The 62nd American Society of Hematology (ASH) annual meeting took place virtually last weekend (December 5-8, 2020). Register for free and check out the many poster presentations and oral abstracts in the Gene Editing, Therapy and Transfer sessions.
Editas Medicine presented new data on another potential treatment for sickle cell disease and ß-thalassemia. The company's EDIT-301 is an experimental, autologous cell therapy medicine and the new data showed that it led to robust fetal haemoglobin (HbF) induction in the patients' erythroid progeny. You can read about the preclinical trial in our comprehensive database.